Low Bioavailability and High Immunogenicity of a New Brand of E. colil-Asparaginase with Active Host Contaminating Proteins

[1]  Marceli de Oliveira Santos.  Estimativa 2018: Incidência de Câncer no Brasil , 2018 .

[2]  T. Reinheckel,et al.  In Vivo Imaging of Antileukemic Drug Asparaginase Reveals a Rapid Macrophage-Mediated Clearance from the Bone Marrow , 2017, The Journal of Nuclear Medicine.

[3]  C. Scrideli,et al.  Shorter Maintenance Therapy in Childhood Acute Lymphoblastic Leukemia: The Experience of the Prospective, Randomized Brazilian GBTLI ALL-93 Protocol , 2016, Front. Pediatr..

[4]  A. Baruchel,et al.  Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation , 2016, Haematologica.

[5]  K. Vinnakota,et al.  Determination of the catalytic mechanism for mitochondrial malate dehydrogenase. , 2015, Biophysical journal.

[6]  Alex Eon-Duval,et al.  Quality attributes of recombinant therapeutic proteins: An assessment of impact on safety and efficacy as part of a quality by design development approach , 2012, Biotechnology progress.

[7]  W. Jiskoot,et al.  Immunogenicity of Therapeutic Proteins: The Use of Animal Models , 2011, Pharmaceutical Research.

[8]  R. Aquino,et al.  Sistema de salud de Brasil , 2011 .

[9]  C. Pui,et al.  L‐asparaginase treatment in acute lymphoblastic leukemia , 2011, Cancer.

[10]  C. Scrideli,et al.  Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group--protocol ALL-99. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Harbott,et al.  Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000 , 2010, Leukemia.

[12]  T. Mok.  Living with imperfection. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Neuberg,et al.  Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985–2000) , 2009, Leukemia.

[14]  Marc N. Offman,et al.  A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L-asparaginase. , 2009, The Journal of clinical investigation.

[15]  K. Ribeiro,et al.  Trends in childhood leukemia mortality in Brazil and correlation with social inequalities , 2007, Cancer.

[16]  Basant Sharma,et al.  Immunogenicity of therapeutic proteins. Part 3: impact of manufacturing changes. , 2007, Biotechnology advances.

[17]  Ruedi Aebersold,et al.  The Need for Guidelines in Publication of Peptide and Protein Identification Data , 2004, Molecular & Cellular Proteomics.

[18]  G. Hempel,et al.  Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum. , 2002, Analytical biochemistry.

[19]  H. Müller,et al.  Use of L-asparaginase in childhood ALL. , 1998, Critical reviews in oncology/hematology.

[20]  J. Boos,et al.  Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia , 1997, British journal of haematology.

[21]  H. Jürgens,et al.  Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. , 1996, European journal of cancer.

[22]  G. Schernthaner,et al.  Immunogenicity and Allergenic Potential of Animal and Human Insulins , 1993, Diabetes Care.

[23]  D. Coppola,et al.  Comparative pharmacokinetic studies of three asparaginase preparations. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  P. Wilton,et al.  Development of Anti‐hGH Antibodies during Therapy with Authentic Human Growth Hormone , 1991, Acta paediatrica Scandinavica. Supplement.

[25]  H. Oettgen,et al.  L‐asparaginase activity in plasma and other biological fluids , 1970, Cancer.

[26]  American Society of Clinical Oncology Statement on the Impact of Utilization Management Policies for Cancer Drug Therapies. , 2017, Journal of oncology practice.

[27]  R. Arceci.  Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group , 2012 .

[28]  C. China Pharmacopoeia,et al.  Pharmacopoeia of the People's Republic of China , 2010 .

[29]  M. Mann,et al.  Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips , 2007, Nature Protocols.

[30]  J. Abrahão.  The health system in Brazil. , 2005, World hospitals and health services : the official journal of the International Hospital Federation.

[31]  A. Richter,et al.  Assays for Controlling Host-Cell Impurities in Biopharmaceuticals , 2005 .